CERS
Price
$1.72
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
One day until earnings call
DXCM
Price
$72.10
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
100 days until earnings call
Ad is loading...

CERS vs DXCM

Header iconCERS vs DXCM Comparison
Open Charts CERS vs DXCMBanner chart's image
Cerus
Price$1.72
Change-$0.00 (-0.00%)
Volume$3.17M
CapitalizationN/A
DexCom
Price$72.10
Change-$0.00 (-0.00%)
Volume$5.57M
CapitalizationN/A
View a ticker or compare two or three
CERS vs DXCM Comparison Chart
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DXCM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CERS vs. DXCM commentary
Oct 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Buy and DXCM is a StrongBuy.

COMPARISON
Comparison
Oct 30, 2024
Stock price -- (CERS: $1.72 vs. DXCM: $72.09)
Brand notoriety: CERS and DXCM are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 251% vs. DXCM: 115%
Market capitalization -- CERS: $342.62M vs. DXCM: $53.47B
CERS [@Medical Specialties] is valued at $342.62M. DXCM’s [@Medical Specialties] market capitalization is $53.47B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileDXCM’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • DXCM’s FA Score: 0 green, 5 red.
According to our system of comparison, DXCM is a better buy in the long-term than CERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while DXCM’s TA Score has 4 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 5 bearish.
  • DXCM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both CERS and DXCM are a bad buy in the short-term.

Price Growth

CERS (@Medical Specialties) experienced а +2.38% price change this week, while DXCM (@Medical Specialties) price change was -0.72% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.01%. For the same industry, the average monthly price growth was +3.93%, and the average quarterly price growth was -2.96%.

Reported Earning Dates

CERS is expected to report earnings on Feb 20, 2025.

DXCM is expected to report earnings on Feb 06, 2025.

Industries' Descriptions

@Medical Specialties (-2.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DXCM($53.5B) has a higher market cap than CERS($343M). CERS YTD gains are higher at: -20.370 vs. DXCM (-41.905). DXCM has higher annual earnings (EBITDA): 917M vs. CERS (-26.34M). DXCM has more cash in the bank: 2.72B vs. CERS (65.9M). CERS has less debt than DXCM: CERS (96M) vs DXCM (2.59B). DXCM has higher revenues than CERS: DXCM (3.62B) vs CERS (156M).
CERSDXCMCERS / DXCM
Capitalization343M53.5B1%
EBITDA-26.34M917M-3%
Gain YTD-20.370-41.90549%
P/E RatioN/A106.11-
Revenue156M3.62B4%
Total Cash65.9M2.72B2%
Total Debt96M2.59B4%
FUNDAMENTALS RATINGS
CERS vs DXCM: Fundamental Ratings
CERS
DXCM
OUTLOOK RATING
1..100
105
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
10066
SMR RATING
1..100
9634
PRICE GROWTH RATING
1..100
6257
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (51) in the Medical Specialties industry is in the same range as DXCM (74). This means that CERS’s stock grew similarly to DXCM’s over the last 12 months.

DXCM's Profit vs Risk Rating (66) in the Medical Specialties industry is somewhat better than the same rating for CERS (100). This means that DXCM’s stock grew somewhat faster than CERS’s over the last 12 months.

DXCM's SMR Rating (34) in the Medical Specialties industry is somewhat better than the same rating for CERS (96). This means that DXCM’s stock grew somewhat faster than CERS’s over the last 12 months.

DXCM's Price Growth Rating (57) in the Medical Specialties industry is in the same range as CERS (62). This means that DXCM’s stock grew similarly to CERS’s over the last 12 months.

DXCM's P/E Growth Rating (97) in the Medical Specialties industry is in the same range as CERS (100). This means that DXCM’s stock grew similarly to CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSDXCM
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
65%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
63%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 21 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 2 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
63%
View a ticker or compare two or three
Ad is loading...
CERS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DXCM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.732.16
+10.50%
GameStop Corp
BTC.X69907.7600001978.460900
+2.91%
Bitcoin cryptocurrency
AAPL233.401.99
+0.86%
Apple
SPY580.831.79
+0.31%
SPDR® S&P 500® ETF Trust
TSLA262.51-6.68
-2.48%
Tesla

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with MASS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then MASS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+2.99%
MASS - CERS
52%
Loosely correlated
+3.04%
FLGT - CERS
48%
Loosely correlated
+2.57%
KIDS - CERS
44%
Loosely correlated
+1.71%
BLFS - CERS
44%
Loosely correlated
+3.77%
BNGO - CERS
44%
Loosely correlated
+1.37%
More

DXCM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then CERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-1.84%
CERS - DXCM
42%
Loosely correlated
+2.99%
IRMD - DXCM
34%
Loosely correlated
+3.42%
AORT - DXCM
33%
Loosely correlated
-0.04%
ACRS - DXCM
33%
Loosely correlated
-4.73%
COO - DXCM
32%
Poorly correlated
-2.14%
More